about

our purpose:
precision medicine

TAmiRNA is a biotech company specialized in the discovery and validation of microRNA biomarkers. Our mission is to provide validated diagnostic solutions to patients with serious aging-related illnesses. We aim to improve and prolong patient stability, health and quality of life with increasing age.

our technology:
microRNA signatures

We are specialized in biomarker development using blood-circulating microRNAs – evolutionary conserved regulators of gene expression and cell/tissue function. We develop diagnostic algorithms (“signatures”) based on the logic combination of microRNA levels and clinical parameters.

our focus:
age-associated diseases

TAmiRNA is actively involved in R&D projects in osteoporosis (OP), cardiovascular disease (CVD), liver disease and aging. OP and CVD are multifactorial illnesses. Using microRNA signatures we aim to decode the contributing disease factors on a personalized level, and to use this knowledge for better diagnosis.

our team

Top Management

Matthias Hackl, PhD

CEO and co-founder

Matthias holds a master’s and doctorate degree in Biotechnology from BOKU University in Vienna. He started his scientific career in 2007 and has since been working in RNA (microRNA) biology. He co-founded TAmiRNA 2013 to develop diagnostic applications for microRNA biomarkers and has been heading the company as CEO|CSO since 2014. In 2016, Matthias co-founded the RNA-silencing company RemuteBio and has acted as a scientific advisor to multiple biotech companies.

Andreas Diendorfer, PhD; MBA

COO and Head of Computational Biology

Andreas B. Diendorfer studied molecular biology at the University of Natural Resources and Life Sciences, Vienna, finishing his Masters in 2015. During his PhD studies at the Austrian Centre of Industrial Biotechnology, he worked on RNAi based cell selection systems for antibody production in CHO cell lines. Including his expertise as freelance software developer, he put a strong focus on computational biology to complement his wet-lab studies. Andreas B. Diendorfer is author and co-author of multiple papers and publications about micro-RNA and RNAi with both an in-vitro and in-silico focus. He joined TAmiRNA in 2019 to establish the in-house data analysis of NGS and qPCR data for biomarker discovery. In 2021 he pursued his MBA studies at the WU Executive Academy in Vienna and supports TAmiRNA as Chief Operations Officer and Head of Computational Biology since 2022.

Otto Kanzler

CFO and co-founder

Otto Kanzler has more than 30 years experience in process- and business development in the biotech industry. Since 2007 he is serving as Management Consultant for production and technology-development for biotech- and pharma- industry, specified for strategic and economic issues. He is a serial entrepreneur having founded and co-founded several companies, all of which are still active – CEO / CFO of Remute Bio GmbH (founded 2016), co-founder and interim CEO / CFO of Phoenestra GmbH (founded 2015), Advisor of DirectSens GmbH (since 2015), co-founder and CFO of Syconium Lactic Acid GmbH (founded 2014), co-founder and CFO of TAmiRNA GmbH (founded 2012), co-founder and CEO of Evercyte GmbH und Chorus GmbH, (both founded 2011). Between 1993 and 2007 he was department head at Boehringer Ingelheim Austria, responsible for the economic issues of the industrial biopharmaceutical business. Prior to this he was head of process development for biopharmaceutical processes at Boehringer Ingelheim Austria (1981-1993).

Business Development & Quality Management

Magdalena Mecking, MSc

Scientific Consultant – Business Development

Magdalena Mecking has studied Molecular Life Science at the University of Lübeck, Germany, and finished her Masters in 2016. Before joining TAmiRNA in 2022, she has worked in the NGS industry for several years and gained profound knowledge of NGS technology, specifically RNA sequencing. Having coordinated >300 NGS services projects with various technologies of small and long RNA sequencing, she has a broad understanding of NGS data and project design. With this background, Magdalena will be the best person to discuss your project setup and consult you on available NGS workflow options.

Elisabeth Semmelrock, PhD

Head of Quality Management

Elisabeth Semmelrock studied human biology at the University of Vienna and Salzburg. After achieving her PhD in 2003 she held PostDoc positions at the Center of Molecular Medicine, Medical University of Graz and University of Natural Resources and Life Sciences Vienna (Boku). Elisabeth Semmelrock is the author and co-author of multiple papers and publications about microRNA. She joined TAmiRNA in 2016 as a Scientific writer and assisted with Marketing and PR. Since 2022 she has been Head of Quality Management and PRRC, and is responsible for the implementation, monitoring, and further development of the quality management system within TAmiRNA.

Teresa Lara Krammer, PhD

Head of R&D

Romana Bischl, MSc

Head of CRO Services

Romana Bischl is Head of CRO Services at TAmiRNA, bringing extensive expertise in cancer immunotherapy, molecular biotechnology, and preclinical development. With a background in leading in vivo and in vitro studies, scRNA-seq analysis, and project coordination, she combines scientific rigor with strategic leadership. Romana holds an MSc in Molecular Biotechnology from FH Campus Wien and pursued her PhD research in immuno-oncology at the Medical University of Vienna. Prior to joining TAmiRNA, she led preclinical development projects at Hookipa Biotech. At TAmiRNA, she oversees contract research services with a focus on innovation, quality, and client collaboration.

Susanna Skalicky, MSc

Scientist

Susanna graduated from FH Wien in 2012 with a master’s degree in biomedical science and joined the TAmiRNA team in 2013. With a keen eye for detail and a passion for advancing the field of miRNA-based diagnostics solutions she has spearheaded our team’s efforts in developing cutting-edge products such as HepatomiR®, and address the need of our clients.

Kseniya Khamina-Kotisch, PhD

Senior Scientist

Kseniya Khamina-Kotisch studied Immunology at the University of Vienna. After achieving her PhD in 2018 she held a PostDoc position at the CeMM Research Center for Molecular Medicine Vienna, where she gained profound knowledge in Next Generation Sequencing. Kseniya Khamina-Kotisch is the author and co-author of multiple papers and publications in the field of microRNA and NGS. She joined TAmiRNA in 2019 as a Senior Scientist and as an expert in small RNAs sequencing, spearheaded the development of the miND spike-ins.

Alexandra Wagner, MSc

Scientist – R&D

Alisia Wagner, BSc

Junior Scientist – CRO Services

Tiina Berg, MSc

Scientist – CRO Services

Marianne Pultar, MSc

Scientist – Computational Biology

Jan Petrzilek, MSc

Scientist – R&D

Jan is a molecular biologist who worked on pioneering research on the kinetic regulation of the microRNA (miRNA) pathway across species and cell types at the Max Perutz Labs, University of Vienna. His academic background includes over a decade of laboratory experience and eight years of specialization in the miRNA field.

At TAmiRNA, Jan contributes his deep expertise in next-generation sequencing (NGS) and computational data analysis. He is passionate about combining experimental biology with data-driven approaches to advance RNA-based diagnostics and biomarker discovery.”

Scientific Advisors

Regina Grillari, PhD assoc Prof.

Scientific advisor and co-founder

Regina Grillari is associate professor for cellular biology since 2008 and has been leading a group focused on cellular immortalization and cell line development for more than 10 years at the Department of Biotechnology, University of Natural Resources and Applied Life Sciences Vienna, Austria. She achieved her PhD in 2000 on immortalization of human cells and recombinant protein expression and was appointed to receive the Prof. Anton Kurir habilitation award in 2009. In 2012 she received the “Phoenix Award” for successful academic entrepreneurship from the Austrian Ministry of Science and Research and 2015 she achieved third place of the Houska Award of the B&C Holding. Furthermore Regina Grillari has authored and co-authored more than 50 scientific publications and book chapters, 4 patents. In addition she is co-founder and CTO of Evercyte GmbH (est. 2011), co-founder of Phoenestra GmbH (2015) and also co-founder and scientific advisor of Remute Bio GmbH (2016).

Johannes Grillari, PhD assoc Prof.

Scientific advisor and co-founder

Johannes Grillari’s research focus is on improving our understanding of the molecular and physiological mechanisms of regeneration, as well as on the impact of cellular senescence on regeneration, specifically in skin and bone. In addition, he is interested in engineering of mammalian cells to establish relevant and standardizable cell model systems and cell factories.

Johannes Grillari has graduated in Biotechnology at the University of Natural Resources and Life Sciences Vienna (BOKU) in Austria, where he also accomplished his PhD in the field of cell aging in 1999. Since then he has founded and is leading the Christian Doppler Laboratory on Biotechnology of Skin Aging at the Department of Biotechnology at BOKU. He has worked as visiting scientist in the lab of Angus Lamond in Dundee, Scotland, in the field of RNA biology. In 2010 he was appointed Associate Professor at BOKU, in 2019 director of the Ludwig Boltzmann Institute of Experimental and Clinical Traumatology, Vienna. He also acted as co-founder in 2011 for Evercyte, a company generating and providing immortalized cells for in vitro toxiciology, biopharmaceutical and cosmetical research and development. In 2013, he co-founded TAmiRNA, a company interested in identifying circulating miRNAs as biomarkers for aging and age-associated diseases, specifically in osteoporosis. He has published more than 140 peer reviewed articles, holds 14 patents and has been invited speaker to more than 130 international conferences and departmental seminars. He has received several awards including the Walter-Doberauer award for aging research.

our partners

AtheroNET COST

Network for implementing multiomics approaches in atherosclerotic cardiovascular disease. TAmiRNA contributes knowledge on microRNA omics analyses.

www.atheronet.eu

Austrian Cluster for Tissue Regeneration

www.tissue-regeneration.at

Austrian Society for Extracellular Vesicles

TAmiRNA is proud member of the ASEV, supporting annual meetings.

https://www.asev.at/home

BioCat GmbH

Distribution Partner for Germany.
https://www1.biocat.com/

Biomedica
Central European Distribution partner
www.bmgrp.com/home/

Biogenity

Collaboration partner including Next-Generation Sequencing (NGS) and bioinformatics analysis tools.

https://biogenity.com/

BioNova

Our exclusive distribution partner for TAmiRNA´s RNA-sequencing services in Spain and Portugal.

https://www.bionova.es

BOKU – VIBT
Partner for assay development and functional in vitro screenings of microRNAs that are associated with age-related disorders.
www.boku.ac.at/vibt.html

Evercyte GmbH
Partner in the application of pre-clinical models for toxicity and efficacy testing of novel drug candidates
www.evercyte.com

Die Österreichische Forschungsförderungsgesellschaft FFG
“Basisprogramm” financing of R&D cooperations of TAmiRNA.
www.ffg.at

Grillari Labs
Partner in development of basic research models to gain a better understanding microRNA function in age-related disorders such as Osteoporosis, Cardiovascular Disease or Neurodegenerative Disease
www.grillarilabs.at

German Society for Extracellular Vesicles

TAmiRNA is proud member of the GSEV, supporting annual meetings.

https://gsev.org/

Innofly Management
Supports TAmiRNA in backoffice activities
www.innofly.at

Ludwig Boltzmann Institute for Experimental and Clinical Traumatology

www.trauma.lbg.ac.at/de

Phoenestra

Partner in the application of omics tools for characterization of microRNAs/mRNAs in stem-cell derived products including exosomes and extracellular vesicles.

https://www.phoenestra.com/